Correlation Between Lumos Pharma and Biocardia

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Lumos Pharma and Biocardia at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Lumos Pharma and Biocardia into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Lumos Pharma and Biocardia, you can compare the effects of market volatilities on Lumos Pharma and Biocardia and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Lumos Pharma with a short position of Biocardia. Check out your portfolio center. Please also check ongoing floating volatility patterns of Lumos Pharma and Biocardia.

Diversification Opportunities for Lumos Pharma and Biocardia

-0.74
  Correlation Coefficient

Pay attention - limited upside

The 3 months correlation between Lumos and Biocardia is -0.74. Overlapping area represents the amount of risk that can be diversified away by holding Lumos Pharma and Biocardia in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Biocardia and Lumos Pharma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Lumos Pharma are associated (or correlated) with Biocardia. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Biocardia has no effect on the direction of Lumos Pharma i.e., Lumos Pharma and Biocardia go up and down completely randomly.

Pair Corralation between Lumos Pharma and Biocardia

Given the investment horizon of 90 days Lumos Pharma is expected to generate 0.62 times more return on investment than Biocardia. However, Lumos Pharma is 1.62 times less risky than Biocardia. It trades about 0.07 of its potential returns per unit of risk. Biocardia is currently generating about -0.07 per unit of risk. If you would invest  387.00  in Lumos Pharma on September 16, 2024 and sell it today you would earn a total of  47.00  from holding Lumos Pharma or generate 12.14% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthWeak
Accuracy96.92%
ValuesDaily Returns

Lumos Pharma  vs.  Biocardia

 Performance 
       Timeline  
Lumos Pharma 

Risk-Adjusted Performance

5 of 100

 
Weak
 
Strong
Modest
Compared to the overall equity markets, risk-adjusted returns on investments in Lumos Pharma are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. In spite of very inconsistent primary indicators, Lumos Pharma displayed solid returns over the last few months and may actually be approaching a breakup point.
Biocardia 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Biocardia has generated negative risk-adjusted returns adding no value to investors with long positions. Despite inconsistent performance in the last few months, the Stock's fundamental indicators remain somewhat strong which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Lumos Pharma and Biocardia Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Lumos Pharma and Biocardia

The main advantage of trading using opposite Lumos Pharma and Biocardia positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Lumos Pharma position performs unexpectedly, Biocardia can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Biocardia will offset losses from the drop in Biocardia's long position.
The idea behind Lumos Pharma and Biocardia pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.

Other Complementary Tools

Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Money Managers
Screen money managers from public funds and ETFs managed around the world
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk